Vidhi Specialty Food Ingredients Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 1 Jun 2026 | Chemicals & Petrochemicals | Market Cap: ₹1.5K Cr
FY27 outlook is robust with expected full utilization of Dahej and Roha facilities. - Sales growth expected from expanded product portfolio focusing on high-margin, value-added products. - Contribution of value-added products expected to double from 5% in FY26 to around 10-12% or more in FY27. - New product lines like CoatIcon tablet coating systems are in aggressive sampling and approval phases with positive feedback, indicating future revenue streams. - Expected capex of INR75-85 crores for new projects at Dahej, starting commercialization mid FY27-'28. - Growth is anticipated from emerging markets (EM) over the next 3-5 years, reducing dependency on the U.S. Vidhi Specialty Food Ingredients expects robust demand and full utilization of Dahej and Roha facilities in FY27.
From Vidhi Specialty Food Ingredients Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹329
Market Cap
₹1.5K Cr
P/E Ratio
28.9
Revenue Rank
Margin Rank
How does Vidhi Specialty Food Ingredients Ltd rank in Chemicals & Petrochemicals?
Compare Vidhi Specialty Food Ingredients Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Vidhi Specialty Food Ingredients Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹123 Cr, net profit ₹13 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →FY27 outlook is robust with expected full utilization of Dahej and Roha facilities.
- →Sales growth expected from expanded product portfolio focusing on high-margin, value-added products.
- →Contribution of value-added products expected to double from 5% in FY26 to around 10-12% or more in FY27.
- →New product lines like CoatIcon tablet coating systems are in aggressive sampling and approval phases with positive feedback, indicating future revenue streams.
- →Expected capex of INR75-85 crores for new projects at Dahej, starting commercialization mid FY27-'28.
- →Growth is anticipated from emerging markets (EM) over the next 3-5 years, reducing dependency on the U.S. market.
- →Once geopolitical conditions improve, demand from certain key markets (Middle East, Philippines, Bangladesh) is expected to increase sharply.
- →Continuous R&D investments support product pipeline with long-term growth visibility over a decade.
📈 Profitability & Margins
Rank 1- →Vidhi Specialty Food Ingredients expects robust demand and full utilization of Dahej and Roha facilities in FY27.
- →EBITDA margins to improve further with increased sales from value-added, high-margin products; current manufacturing EBITDA margin near 24-25%.
- →Contribution from high-margin value-added products expected to double in FY27 (from ~5% in FY26 to 10-12% or more).
- →New product lines like CoatIcon (pharma coating) in aggressive sampling, with commissioning expected mid FY27-28, anticipated to contribute to growth.
- →Capex of INR75-85 crores planned for new product segments, targeted to drive sales of INR125-150 crores upon commissioning.
- →Continuous R&D investments with over 60 chemists and INR4.5-5 crores spent on analytical equipment underpin long-term innovation pipeline.
- →Return on Equity expected to remain around the current ~15% band.
- →Overall, company optimistic about sustained earnings growth driven by operational efficiencies, product mix optimization, and expanding specialty offerings.
🏗️ Capital Expenditure Plans
Yes- →Vidhi Specialty Food Ingredients plans capex of INR75-85 crores for a new project at Dahej, expected to commission in 18 months (mid-FY27-28).
- →Additional capex of INR5-12 crores for scaling up the pharma product line (CoatIcon tablet coating system).
- →Capex primarily targeted towards expanding capacity for new high-margin, value-added products in pharma, cosmetics, and pigment segments.
- →Investments are focused on enhancing manufacturing capabilities and commercialization of emerging products from robust R&D pipelines.
- →The company is committed to strategic investments in technology, infrastructure, product development, and human capital to support long-term growth.
- →The R&D expenditure includes INR4.5-5 crores on analytical equipment alone, showing a continuous focus on innovation.
- →The investments aim to double the contribution of value-added products from 5% to approximately 10-12% in FY27.
💰 Fundraising & Capital Structure
No information- →The transcript does not mention any current or planned fundraising through debt or equity.
- →The company has highlighted capex investments of INR 75-85 crores for new projects at Dahej and INR 5-12 crores for pharma product line (CoatIcon).
- →No mention of raising funds via equity or debt to finance these investments; instead, management emphasizes strong balance sheet, low debt-to-equity ratio (0.28%), and prudent fiscal management.
- →Increased interest cost is due to withdrawal of export finance subvention by the government, not new borrowing.
- →Overall, the company appears to be funding growth internally without external equity or debt issuance at this time.
📋 Order Book & Pipeline
No information- →The transcript does not explicitly mention the current or expected order book or pending orders in precise numbers.
- →However, management expresses strong confidence in demand, expecting full capacity utilization at both Dahej and Roha facilities in FY27.
- →The order pipeline seems robust, supported by ongoing sampling and approvals for new products like the CoatIcon tablet coating system, with approvals expected within about 6 months.
- →They anticipate growth in value-added and specialty products, doubling contribution from 5% to around 10-12% in FY27.
- →The management is optimistic about improved sales and scaling up new product lines post-capex commissioning in mid-FY27-28.
- →Customer demand is expected to rebound as geopolitical situations improve, signaling healthy future order inflows across markets.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Vidhi Specialty Food Ingredients Ltd Q4 FY26 results?
FY27 outlook is robust with expected full utilization of Dahej and Roha facilities. - Sales growth expected from expanded product portfolio focusing on high-margin, value-added products. - Contribution of value-added products expected to double from 5% in FY26 to around 10-12% or more in FY27. - New product lines like CoatIcon tablet coating systems are in aggressive sampling and approval phases with positive feedback, indicating future revenue streams. - Expected capex of INR75-85 crores for new projects at Dahej, starting commercialization mid FY27-'28. - Growth is anticipated from emerging markets (EM) over the next 3-5 years, reducing dependency on the U.S. Vidhi Specialty Food Ingredients expects robust demand and full utilization of Dahej and Roha facilities in FY27.
What is Vidhi Specialty Food Ingredients Ltd share price analysis?
Vidhi Specialty Food Ingredients Ltd currently shows a below-average growth signal. The stock trades at a P/E of 28.9 with a market cap of ₹1,548 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vidhi Specialty Food Ingredients Ltd planning capital expenditure?
Vidhi Specialty Food Ingredients plans capex of INR75-85 crores for a new project at Dahej, expected to commission in 18 months (mid-FY27-28).
Keep Vidhi Specialty Food Ingredients Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.